Latest Breaking News On - Stefan riley - Page 5 : comparemela.com

Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in a Phase 1b Trial of INZ-701

BOSTON, June 27, 2023 (GLOBE NEWSWIRE) Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation,

Inozyme Pharma Reports First Quarter 2023 Financial Results and Provides Business Highlights

Inozyme Pharma Reports Inducement Grants Under Nasdaq

BOSTON, May 03, 2023 (GLOBE NEWSWIRE) Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel.

Inozyme Pharma Reports Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701

16.02.2023 - - Rapid, significant, and sustained increase in plasma pyrophosphate (PPi) observed and encouraging patient reported outcome data in all dose cohorts in ENPP1 Deficiency trial - - Rapid and significant increase in PPi observed in all dose cohorts .

Inozyme Pharma Announces Peer-Reviewed Publication Revealing Increased Prevalence of ENPP1 Deficiency

- Article in Orphanet Journal of Rare Diseases estimates genetic prevalence of ENPP1 Deficiency at 1 in 64,000 pregnancies, more than tripling prior estimate - - Company estimates addressable patient. | December 5, 2022